Document is current
Any future updates will be listed below
-
Authors
Cogram, Patricia https://orcid.org/0000-0002-4198-0821
Alkon, Daniel L.
Crockford, David
Deacon, Robert M. J.
Hurley, Michael J.
Altimiras, Francisco https://orcid.org/0000-0003-1992-8338
Sun, Miao-Kun
Tranfaglia, Michael
-
Funding
Funding for this research was provided by:
FRAXA Research Foundation
- License Information
-
More Information
Article History
Received: 3 October 2019
Accepted: 5 October 2020
First Online: 22 October 2020
Competing interests
: The authors declare no competing interests. Research support (including salaries, equipment, supplies, and other expenses) was provided by FRAXA Research Foundation, a no-for profit organization, that do not gain or lose financially through this publication. Drs. Robert Deacon, Michael Hurley, Francisco Altimiras and Patricia Cogram were supported under a FRAXA grant. Dr. Michael Tranfaglia is the medical director of FRAXA Research Foundation and has no conflict of interest in supporting this work. The experiments using Bryostatin1 for FXS were conducted when the authors, Drs. Alkon and Sun were full-time employees of the Blanchette Rockefeller Neurosciences Institute, USA. Dr. David Crockford, from Neurotrope Bioscience Inc., USA, provided Bryostatin 1 for the experimental work for this publication.
